Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L125247-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $118.90 | |
L125247-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $190.90 | |
L125247-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $532.90 |
Potent Hedgehog signaling pathway inhibitor
Synonyms | CCG-269788 | BCP9000881 | DTXSID50154986 | Taladegib (LY2940680) | EX-A156 | LY 2940680 | NCGC00263170-06 | J-515412 | 1258861-20-9 | DB12550 | UNII-QY8BWX1LJ5 | 1KS | IEISBKIVLDXSMZ-UHFFFAOYSA-N | MFCD21609264 | R06AD04 | Taladegib | HMS2230I06 | LY29406 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant\xa0Smoothened gene mutation. Has anti-tumor activity in animal models. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Smoothened homolog antagonist |
Note | Toxic, refer to SDS for further information . Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2. |
ALogP | 4.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 4-fluoro-N-methyl-N-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-2-(trifluoromethyl)benzamide |
---|---|
INCHI | InChI=1S/C26H24F4N6O/c1-34(25(37)20-8-7-16(27)15-21(20)26(28,29)30)17-10-13-36(14-11-17)24-19-6-4-3-5-18(19)23(32-33-24)22-9-12-31-35(22)2/h3-9,12,15,17H,10-11,13-14H2,1-2H3 |
InChi Key | SZBGQDXLNMELTB-UHFFFAOYSA-N |
Canonical SMILES | CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F |
Isomeric SMILES | CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F |
PubChem CID | 49848070 |
Molecular Weight | 512.5 |
CAS Registry No. | 1258861-20-9 |
---|---|
PubChem CID | 49848070 |
ChEMBL Ligand | CHEMBL2142592 |
RCSB PDB Ligand | 1KS |
GPCRdb Ligand | taladegib |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
J1520093 | Certificate of Analysis | May 10, 2023 | L125247 |
Solubility | DMSO 0.66 mg/mL (1.28 mM); Water <1 mg/mL (<1 mM); Ethanol 2 mg/mL (3.9 mM) |
---|
Pictogram(s) | GHS08 |
---|---|
Signal | Danger |
Hazard Statements | H373:Causes damage to organs through prolonged or repeated exposure H360:May damage fertility or the unborn child |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P260:Do not breathe dust/fume/gas/mist/vapors/spray. P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. P319:Get medical help if you feel unwell. |
1. Lu X, Peng Y, Wang C, Yang J, Bao X, Dong Q, Zhao W, Tan W, Dong X. (2017) Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.. Eur J Med Chem, 138 (13): (384-395). [PMID:28688278] [10.1021/op500134e] |
2. Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, Tiu RV, Pitou C, Tucker T, Brail L et al.. (2018) Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.. Clin Cancer Res, 24 (9): (2082-2091). [PMID:29483143] [10.1021/op500134e] |